Physician profile
Samuel Apeatu
NPI 1013939545
$2,716.35
in general payments reported to CMS, 2019-2025
24 companies · $708 in 2025
The $708 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $59.03 · 2021: $544 · 2022: $397 · 2023: $184 · 2024: $824 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,715.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $738.67 | 2023-2025 | Qelbree, Qelbree |
| Neurelis, INC. | $401.62 | 2021-2025 | Valtoco |
| Biohaven Pharmaceutical Holding Company LTD. | $184.16 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $154.63 | 2020-2025 | Austedo Xr, Austedo Xr |
| Lundbeck LLC | $153.10 | 2023-2025 | Vyepti |
| Sk Life Science, INC. | $147.26 | 2021 | |
| Allergan, INC. | $145.38 | 2021 | |
| Eisai INC. | $109.07 | 2022-2024 | |
| Jazz Pharmaceuticals INC. | $93.58 | 2023-2025 | |
| Corium, LLC | $89.76 | 2024-2025 | Azstarys |
| Ucb, INC. | $88.83 | 2021-2022 | |
| Abbvie INC. | $81.72 | 2023-2024 | Ubrelvy, Botox |
| Neurocrine Biosciences, INC. | $80.88 | 2021-2024 | Ingrezza |
| Arbor Pharmaceuticals, INC. | $33.10 | 2022 | |
| Acadia Pharmaceuticals INC | $30.68 | 2023 | Daybue |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tanabe Pharma America, INC. | $28.88 | 2024 | |
| Amneal Pharmaceuticals LLC | $27.53 | 2024 | Rytary |
| Tg Therapeutics, INC. | $24.06 | 2024 | |
| Lilly USA, LLC | $22.66 | 2023 | Emgality, Reyvow |
| Biomarin Pharmaceutical INC. | $19.49 | 2020 | |
| Harmony Biosciences LLC | $17.12 | 2021 | |
| Argenx US, INC. | $15.76 | 2025 | Vyvgart Hytrulo |
| Greenwich Biosciences, INC. | $14.42 | 2021 | |
| Biogen, INC. | $13.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Apeatu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.